Vermillion Takes Control: Dx Firm Launches Its Own Lab To Market Ovarian Cancer Test
This article was originally published in The Gray Sheet
Executive Summary
Not happy with market penetration since its FDA-cleared OVA1 ovarian cancer molecular assay launched exclusively via Quest Diagnostics in 2009, Vermillion has launched ASPiRA Labs to more directly connect with OB-GYN customers.
You may also be interested in...
Quest, Vermillion Begin U.S. Marketing Push For Ovarian Cancer Test
Quest Diagnostics will leverage its know-how of the women's health care segment and relationships with OB/GYNs to market Vermillion's OVA1, the first FDA-cleared blood test to help assess potentially malignant ovarian tumors prior to surgery
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.